Sign in
Taking people in United StatesPhase 3

Tests zilovertamab vedotin with standard chemotherapy for previously untreated diffuse large B-cell lymphoma

Tests zilovertamab vedotin with standard chemotherapy in adults with untreated diffuse large B-cell lymphoma.

Key facts

Who runs it
Merck Sharp & Dohme LLC
Where
Albany, Alexandria, Ann Arbor, Athens, Belleville, Bethesda, Billings, Bridgeton, Charlottesville, Cincinnati, Clermont, Columbia, Dallas, Detroit, Eugene, Fargo, Fort Wayne, Fullerton, Gilbert, Golden, Grand Rapids, Greenville, Hampton, Hialeah, Hinsdale, Houston, Jackson, Kansas City, Knoxville, La Crosse, Las Vegas, Lexington, Long Beach, Los Alamitos, Los Angeles, Louisville, Lubbock, Madison, Mobile, Naperville, Nashville, New York, O'Fallon, Ocoee, Olympia, Orange City, Owensboro, Phoenix, Portland, Reno, Richmond, Roanoke, Saginaw, San Francisco, Shirley, Sioux Falls, Springfield, Tampa, The Woodlands, Topeka, and Tucson, United StatesSee the 65 sitesAlso in 34 other countries, 225 sites
Trial code
Registry title
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Status
Recruiting
Phase
Phase 3
People taking part
1,046 people, planned
Started
27 Jan 2025
Expected to end
29 Mar 2032
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Zilovertamab vedotin
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Rituximab Biosimilar
  • Prednisone
  • Prednisolone
  • Vincristine
  • Rescue medication
  • Methylprednisolone
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with diffuse large B-cell lymphoma (DLBCL) who have not had any treatment for it yet.

Age
18 years or older
Sex
All sexes can join.
Disease stage
DLBCL confirmed by a past biopsy. PET scan shows active disease (4 to 5 on the Lugano 5-point scale). Stage I disease cannot join.
Earlier treatment
No earlier treatment for DLBCL.

Main reasons for not taking part

  • Lymphoma that changed from a slow-growing lymphoma into DLBCL
  • Primary mediastinal B-cell lymphoma or Grey zone lymphoma
  • Active lymphoma in the brain or spinal cord (CNS)
  • Serious active heart disease
  • Earlier donor tissue or solid organ transplant

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues
  • Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale
  • Has received no prior treatment for their DLBCL
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization
  • Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)
  • Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)
  • Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening

Who cannot take part

  • Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma
  • Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication
  • Has ongoing corticosteroid therapy
  • Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
  • Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection
  • Has a history of transformation of indolent disease to DLBCL
  • Has a demyelinating form of Charcot-Marie-Tooth disease
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 2 years
  • Has active autoimmune disease that has required systemic treatment in the past 2 years
  • Has active infection requiring systemic therapy
  • Has history of allogeneic tissue/solid organ transplant
  • Has Ann Arbor Stage I DLBCL
  • Has clinically significant pericardial or pleural effusion
  • Has ongoing Grade >1 peripheral neuropathy
  • Known active central nervous system (CNS) lymphoma

Where in United States

Also in 34 other countries, 225 sites

  • New York Oncology Hematology, P.C. (Site 0129)Albany, United StatesContact: Study CoordinatorTaking people
  • CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care (Site 0184)Alexandria, United StatesContact: Study CoordinatorTaking people
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor (Site 9545)Ann Arbor, United StatesContact: Study CoordinatorTaking people
  • University Cancer & Blood Center, LLC (Site 0141)Athens, United StatesContact: Study CoordinatorTaking people
  • New Jersey Cancer Care (Site 7002)Belleville, United StatesContact: Study CoordinatorTaking people
  • American Oncology Partners, P.A. (Site 0185)Bethesda, United StatesContact: Study CoordinatorTaking people
  • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana (Site 0178)Billings, United StatesContact: Study CoordinatorTaking people
  • Circuit Clinical - SSM Health Cancer Care DePaul (Site 0166)Bridgeton, United StatesContact: Study CoordinatorTaking people
  • University of Virginia Cancer Center (Site 0138)Charlottesville, United StatesContact: Study CoordinatorTaking people
  • Oncology_Hematology Care Clinical Trials, LLC (OHC) (Site 8002)Cincinnati, United StatesContact: Study CoordinatorTaking people
  • Clermont Oncology Center (Site 0182)Clermont, United StatesContact: Study CoordinatorTaking people
  • Maryland Oncology Hematology (MOH) (Site 8004)Columbia, United StatesContact: Study CoordinatorTaking people
  • University of Missouri Hospital (Site 0175)Columbia, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology - DFW (Site 8000)Dallas, United StatesContact: Study CoordinatorTaking people
  • Karmanos Cancer Institute (Site 0174)Detroit, United StatesContact: Study CoordinatorTaking people
  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) (Site 8001)Eugene, United StatesContact: Study CoordinatorTaking people
  • Sanford Health Roger Maris Cancer Center (Site 0189)Fargo, United StatesContact: Study CoordinatorTaking people
  • Fort Wayne Medical Oncology and Hematology (Site 0149)Fort Wayne, United StatesContact: Study CoordinatorTaking people
  • Providence Medical Foundation-Oncology (Site 0168)Fullerton, United StatesContact: Study CoordinatorTaking people
  • Banner MD Anderson Cancer Center (Site 0165)Gilbert, United StatesContact: Study CoordinatorTaking people
  • Lutheran Hospital - Cancer Centers of Colorado (Site 0180)Golden, United StatesContact: Study CoordinatorTaking people
  • Corewell Health (Site 0130)Grand Rapids, United StatesContact: Study CoordinatorTaking people
  • East Carolina University (Site 0159)Greenville, United StatesContact: Study CoordinatorTaking people
  • Prisma Health - Upstate (Site 0158)Greenville, United StatesContact: Study CoordinatorTaking people
  • Virginia Oncology Associates (VOA) (Site 8005)Hampton, United StatesContact: Study CoordinatorTaking people
  • Bioresearch Partner (Site 0157)Hialeah, United StatesContact: Study CoordinatorTaking people
  • Hope and Healing Cancer Services (Site 9511)Hinsdale, United StatesContact: Study CoordinatorTaking people
  • Houston Methodist Cancer Center (Site 0154)Houston, United StatesContact: Study CoordinatorTaking people
  • Center for Oncology and Blood Disorders (Site 0153)Houston, United StatesContact: Toll Free NumberNo longer taking part
  • The University of Mississippi Medical Center (Site 0161)Jackson, United StatesContact: Study CoordinatorTaking people
  • Truman Medical Center (Site 0122)Kansas City, United StatesContact: Study CoordinatorTaking people
  • The University of Tennessee Medical Center (Site 0142)Knoxville, United StatesContact: Study CoordinatorTaking people
  • Gunderson Health System (Site 9563)La Crosse, United StatesContact: Study CoordinatorTaking people
  • Comprehensive Cancer Centers of Nevada (Site 0113)Las Vegas, United StatesContact: Study CoordinatorTaking people
  • OptumCare Cancer Care (Site 0121)Las Vegas, United StatesContact: Study CoordinatorTaking people
  • University of Kentucky (Site 0106)Lexington, United StatesContact: Study CoordinatorTaking people
  • MemorialCare Health System - Long Beach Medical Center (Site 9559)Long Beach, United StatesContact: Study CoordinatorTaking people
  • Cancer Blood and Specialty Clinic (Site 0109)Los Alamitos, United StatesContact: Study CoordinatorTaking people
  • Cedars-Sinai Medical Center (Site 0115)Los Angeles, United StatesContact: Study CoordinatorTaking people
  • Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews (Site 0163)Louisville, United StatesContact: Study CoordinatorTaking people
  • Joe Arrington Cancer Research and Treatment Center (Site 0183)Lubbock, United StatesContact: Study CoordinatorTaking people
  • SSM Health Dean Medical Group (Site 0140)Madison, United StatesContact: Study CoordinatorTaking people
  • USA Mitchell Cancer Institute (Site 0173)Mobile, United StatesContact: Study CoordinatorTaking people
  • Edward Cancer Center (Site 0197)Naperville, United StatesContact: Study CoordinatorTaking people
  • SCRI Oncology Partners (Site 7000)Nashville, United StatesContact: Study CoordinatorTaking people
  • Icahn School of Medicine at Mount Sinai (Site 0164)New York, United StatesContact: Study CoordinatorTaking people
  • Cancer Care Specialists of Illinois (Site 0152)O'Fallon, United StatesContact: Study CoordinatorTaking people
  • Orlando Health Cancer Institute (Site 0169)Ocoee, United StatesContact: Study CoordinatorTaking people
  • Vista Oncology (Site 4201)Olympia, United StatesContact: Study CoordinatorTaking people
  • Mid Florida Hematology and Oncology Center (Site 0172)Orange City, United StatesContact: Study CoordinatorTaking people
  • Owensboro Medical Health System (Site 0195)Owensboro, United StatesContact: Study CoordinatorTaking people
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix (Site 0167)Phoenix, United StatesContact: Study CoordinatorTaking people
  • Kaiser Permanente Interstate Medical Office - Central (Site 0181)Portland, United StatesContact: Study CoordinatorTaking people
  • Cancer Care Specialists (Site 9582)Reno, United StatesContact: Study CoordinatorTaking people
  • Virginia Cancer Institute (Site 0148)Richmond, United StatesContact: Study CoordinatorTaking people
  • Blue Ridge Cancer Care (Site 0132)Roanoke, United StatesContact: Study CoordinatorTaking people
  • Central Michigan University - Saginaw (Site 0198)Saginaw, United StatesContact: Study CoordinatorTaking people
  • Pacific Hematology Oncology Associates (Site 0131)San Francisco, United StatesContact: Study CoordinatorTaking people
  • New York Cancer and Blood Specialists (Site 9000)Shirley, United StatesContact: Study CoordinatorTaking people
  • Sanford Cancer Center (Site 0143)Sioux Falls, United StatesContact: Study CoordinatorTaking people
  • Oncology and Hematology Associates (Site 9546)Springfield, United StatesContact: Study CoordinatorTaking people
  • Tampa General Hospital (Site 0134)Tampa, United StatesContact: Study CoordinatorTaking people
  • Texas Oncology-The Woodlands (Site 8003)The Woodlands, United StatesContact: Study CoordinatorTaking people
  • Cotton O'Neil Cancer Center (Site 0108)Topeka, United StatesContact: Toll Free NumberNo longer taking part
  • The University of Arizona Cancer Center - North Campus (Site 0124)Tucson, United StatesContact: Study CoordinatorTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

The 2 groups in the trial

  • Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP)Treatment being tested

    Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months) plus they may receive 2 additional cycles of rituximab or biosimilar as determined by the investigator. Participants also receive 100 mg prednisone, prednisolone, or methylprednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months).

    Treatment: Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Rescue medication, and Methylprednisolone

  • Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP)Existing treatment, for comparison

    Participants receive 750 mg/m\^2 cyclophosphamide, 50 mg/m\^2 doxorubicin, and 375 mg/m\^2 rituximab or rituximab biosimilar, 1.4 mg/m\^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months) plus they may receive 2 additional cycles of rituximab or biosimilar as determined by the investigator. Participants also receive 100 mg prednisone, prednisolone, or methylprednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months).

    Treatment: Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Vincristine, and Methylprednisolone

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)
Plain-language title
Tests zilovertamab vedotin with standard chemotherapy for previously untreated diffuse large B-cell lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026